SCHEMBL824409

SCHEMBL824409

c1cc2c3c(cccc3c1)-c1nc3cc(-c4ccc5nc6c(nc5c4)-c4cccc5cccc-6c45)ccc3nc1-2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.59
PIK3R1 P27986 5/20 0.42
PIK3CA P42336 5/20 0.42
ALDH1A1 P00352 5/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
HSD17B10 Q99714 2/20 0.42
HPGD P15428 2/20 0.42
TP53 P04637 2/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HIF1A Q16665 1/20 0.42
ATM Q13315 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 1/20 0.40
CES2 O00748 1/20 0.39
BCHE P06276 1/20 0.39
CES1 P23141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11728344 0.93 CYP1A2 (0.54) CYP1A2PIK3R1PIK3CAALDH1A1TSHR
SCHEMBL12874082 0.86 CYP1A2 (0.59) CYP1A2ALDH1A1TSHRMAPK1HSD17B10
SCHEMBL29867529 0.82 ALDH1A1 (0.58) CYP1A2ALDH1A1TSHRMAPK1HSD17B10
SCHEMBL903607 0.82 ALDH1A1 (0.58) CYP1A2ALDH1A1TSHRMAPK1HSD17B10
SCHEMBL13706140 0.82 CYP1A2 (0.44) CYP1A2PIK3R1PIK3CAALDH1A1TSHR
SCHEMBL11726205 0.81 CYP1A2 (0.56) CYP1A2PIK3R1PIK3CAALDH1A1TSHR
SCHEMBL3830394 0.81 MAPT (0.61) CYP1A2ALDH1A1TSHRMAPK1HSD17B10
SCHEMBL824394 0.81 CYP1A2 (0.58) CYP1A2ALDH1A1TSHRMAPK1HSD17B10
SCHEMBL31187046 0.81 CYP1A2 (0.58) CYP1A2ALDH1A1TSHRMAPK1HSD17B10
SCHEMBL14336215 0.80 CYP1A2 (0.42) CYP1A2PIK3R1PIK3CATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3261759-B1 SELF-HEALING CAPACITOR AND METHODS OF PRODUCTION THEREOF CAPACITOR SCIENCES INC (US) 2020-05-06 EP disclosed
US-10347423-B2 Solid multilayer structure as semiproduct for meta-capacitor CAPACITOR SCIENCES INCORPORATED (US) 2019-07-09 US disclosed
US-RE47117-E1 Compensated in-plane switching mode liquid crystal display CRYSOPTIX K.K. (JP) 2018-11-06 US disclosed
US-20180114641-A1 SOLID MULTILAYER STRUCTURE AS SEMIPRODUCT FOR META-CAPACITOR CAPACITOR SCIENCES INCORPORATED 2018-04-26 US disclosed
US-20180114641-A1 SOLID MULTILAYER STRUCTURE AS SEMIPRODUCT FOR META-CAPACITOR CAPACITOR SCIENCES INCORPORATED 2018-04-26 US disclosed
US-9916931-B2 Energy storage devices and methods of production thereof CAPACITOR SCIENCE INCORPORATED (US) 2018-03-13 US disclosed
US-9916931-B2 Energy storage devices and methods of production thereof CAPACITOR SCIENCE INCORPORATED (US) 2018-03-13 US disclosed
US-9852846-B2 Self-healing capacitor and methods of production thereof CAPACITOR SCIENCES INCORPORATED (US) 2017-12-26 US disclosed
US-9852846-B2 Self-healing capacitor and methods of production thereof CAPACITOR SCIENCES INCORPORATED (US) 2017-12-26 US disclosed
US-20160314901-A1 ENERGY STORAGE DEVICES AND METHODS OF PRODUCTION THEREOF CAPACITOR SCIENCE INCORPORATED 2016-10-27 US disclosed
WO-2009130676-A2 COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL CRYSOPTIX KK (JP) 2009-10-29 WO disclosed
US-20090268136-A1 Color Liquid Crystal Display and Compensation Panel CRYSOPTIX KK (JP) 2009-10-29 US disclosed
US-20090161037-A1 Backlight Module and Liquid Crystal Display Incorporating the Same CRYSOPTIX KK (JP) 2009-06-25 US disclosed
US-20090161037-A1 Backlight Module and Liquid Crystal Display Incorporating the Same CRYSOPTIX KK (JP) 2009-06-25 US disclosed
WO-2009037565-A2 COLOUR LIQUID CRYSTAL DISPLAY AND PATTERNED COMPENSATION PANEL CRYSOPTIX K.K. (GB) 2009-03-26 WO disclosed
WO-2008142635-A2 COMPENSATED IN-PLANE SWITCHING MODE LIQUID CRYSTAL DISPLAY CRYSOPTIX KK (GB) 2008-11-27 WO disclosed
US-20080224095-A1 BIREFRINGENT FILM, POLYCYCLIC COMPOUND, COATING LIQUID, AND IMAGE DISPLAY DEVICE NITTO DENKO CORPORATION (JP) 2008-09-18 US disclosed
US-20080224095-A1 BIREFRINGENT FILM, POLYCYCLIC COMPOUND, COATING LIQUID, AND IMAGE DISPLAY DEVICE NITTO DENKO CORPORATION (JP) 2008-09-18 US disclosed
US-20080224095-A1 BIREFRINGENT FILM, POLYCYCLIC COMPOUND, COATING LIQUID, AND IMAGE DISPLAY DEVICE NITTO DENKO CORPORATION (JP) 2008-09-18 US disclosed
WO-2007122389-A2 BACKLIGHT MODULE AND LIQUID CRYSTAL DISPLAY INCORPORATING THE SAME CRYSOPTIX K.K. (JP) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080224095-A1 BIREFRINGENT FILM, POLYCYCLIC COMPOUND, COATING LIQUID, AND IMAGE DISPLAY DEVICE CIAPIN1, PYM1, AQP1 CYP1A2 2453/4885PIK3R1 1124/4885PIK3CA 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.